PERTH, Australia – Stem cell therapy company Mesoblast Ltd. provided new subgroup analyses from its phase III advanced chronic heart failure trial showing a greater treatment benefit from rexlemestrocel-L in high-risk patients with chronic heart failure and low ejection fraction (HFrEF) with diabetes or ischemia.
Japan’s Ministry of Health, Labour and Welfare approved Takeda Pharmaceutical Co. Ltd.’s Alofisel (darvadstrocel) to treat complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease. This marks the first allogeneic stem cell therapy to be greenlighted in the country.
Hebecell Corp. closed on a $53 million series A funding to continue advancing its off-the-shelf pluripotent stem cell CAR-natural killer cell (PSC-CAR-NK) therapy program into the clinic. Allen Feng, Hebecell’s chief scientific officer, has worked in stem cell development for more than 16 years. He’s seen a lot of technological change, especially in the past two years. Everyone is using the same technology, he said, but added that Hebecell’s technology is different from anyone else’s. It’s much simpler technology and has “very good potential” to move into large-scale industrial production.
Multiple companies are pursuing CD47-blockade as a tumor immunotherapy approach. Sana Biotechnology Inc., too, is interested in the therapeutic potential of CD47 – but from a very different angle. By overexpressing CD47 on stem cells, researchers at Sana want to make transplanted cells invisible to the immune system.
Researchers at the Walter and Eliza Hall Institute for Medical Research in Melbourne, Australia, have used a newly developed single-cell clonal multiomics technique to gain a better understanding of the genetic programming underlying how stem cells differentiate into particular cell types.
Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell 66.3% to $4.02 on Nov. 17 following news that its autologous cell therapy candidate, Nurown, missed the primary efficacy endpoint of a phase III amyotrophic lateral sclerosis (ALS) study.
Though Quralis Corp., of Cambridge, Mass., has been developing its pipeline for more than three years, the company now has a $42 million series A in hand to continue researching and developing therapies for amyotrophic lateral sclerosis and frontotemporal dementia.
In its first step into Japan, Agex Therapeutics Inc. accelerates its development of engineering hypoimmunogenic cells, universal cells that can be used on patients who didn’t generate the original cell and without the need to use immunosuppressants.
A study published in the Nov. 27, 2019, advance online issue of Nature manages a rare feat. It is both a vindication of and egg in the face for cardiac stem cell research. The good news is that cardiac stem cell transplantation after a heart attack does improve heart function, although the effect is “mild,” Jeffery Molkentin told BioWorld.